HIMS stock

The investor said that Hims now has enough scale and capital to aggressively consolidate smaller telehealth rivals such…

JPMorgan initiated coverage of Hims & Hers with an ‘Overweight’ rating and a price target of $35, according…

The development follows Novo Nordisk’s decision to drop its patent-infringement lawsuit tied to compounded GLP-1 offerings previously marketed…

The company stated that people who sign up for the waitlist will gain priority access to the official…

Hims & Hers’ offices are located in one of those glass buildings in San Francisco, where startup…

Hunterbrook had shorted Hims in 2024, warning its GLP-1 strategy relied on a regulatory loophole during drug shortages…

BMO Capital maintained its ‘Market Perform’ rating for Novo Nordisk, with a price target of $45, implying an…

Hims & Hers also stated that it will no longer advertise compounded GLP-1 offerings on its platform or…

Short interest totalled about $1.39 billion, or roughly 42.83% of the float, according to S3 Partners. Citigroup upgraded…

Shares of Hims & Hers Health surged in premarket trading on Monday following reports that Novo Nordisk may…

Lupton Capital CEO Jonah Lupton said the potential agreement could include both injectable and oral GLP-1 drugs. The…

HIMS Stock Crashes Overnight After Brutal Q1 — But An Investor Says Novo, Lilly Deals Could Make It ‘Netflix Of Healthcare’